Acadia falls after Alzheimer's-related drug narrowly misses goal in study

Acadia Pharmaceuticals

24/09/2026 12:26

** Acadia Pharmaceuticals ACAD.O shares fall 15.6% to $21.45 premarket
** Co says its experimental drug remlifanserin narrowly missed main goal in mid-stage trial
** The study tested remlifanserin for the treatment of hallucinations and delusions associated with Alzheimer's disease psychosis (ADP)
** Company says trends suggest continuing development of 60 mg once-daily dose in ADP
** Acadia plans to continue enrolling its two ongoing late-stage studies evaluating remlifanserin in ADP 
** Alzheimer's disease psychosis involves experiencing hallucinations and delusions driven by physical brain changes
** Up to last close, stock down ~5% YTD

 (Reporting by Sriparna Roy in Bengaluru)
 ((Sriparna.Roy@thomsonreuters.com;))